Senolytics for Secondary Progressive MS
This study is testing if a treatment called senolytic therapy is safe and possible for people with secondary progressive multiple sclerosis (SPMS). The treatment involves taking two medicines, dasatinib and quercetin, by mouth every two weeks for three months. These medicines work by removing old, damaged cells that can cause inflammation and slow down nerve repair. The study is looking for adults aged 50-85 with SPMS whose symptoms have been getting worse and who are not currently taking certain MS medications. Researchers will be watching to see how many people stay in the study, how easy it is to recruit participants, and if there are any side effects from the medicines. Participants will be followed for one year to see the effects of the treatment.
- Study design
- This is an interventional study planning to enroll 30 participants. It is testing a specific drug combination.
- What's involved
- You would take dasatinib and quercetin by mouth every two weeks for three months. You would also be monitored for one year after joining the study.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for one year from enrollment to monitor for treatment effects.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Senolytics for Secondary Progressive MS
At a glance
Conditions
NCT07270120
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Ohio State Martha Morehouse Outpatient Care
Columbus, Ohiostudy coordinator listed
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Participant retention rateBaseline until 3 months
Participant retention rate with D+Q therapy with no more than one missed study visit
- Recruitment feasibilityBaseline
The number of subjects screened to identify eligible participants
- Frequency of adverse drug effects of dasatinib and quercetinFrom baseline through study completion at 1 year
Frequency of adverse drug effects of dasatinib and quercetin